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Abstract
Background: In treatment-refractory liver dominant metastatic colorectal cancer, the role of liver directed therapies
still is unclear. We sought to determine a prognostic score for Y90 radioembolization in these patients.
Methods: We analyzed 106 patients with refractory liver dominant mCRC who had undergone a total of 178 Y90
radioembolizations with resin microspheres was collected. Potential factors influencing survival were analyzed using
a Cox regression. The Log rank test served to establish prognostic factors and to form a clinical score for outcome
prediction after Y90 radioembolization.
Results: Median survival of all patients was 6.7 months. Neither age nor prior surgical or systemic therapy nor
metastatic spread had an effect on survival. In contrast, hepatic tumor load, Karnofsky index as well as CEA and
CA19-9 serums level had a significant influence (p < 0.001, p = 0.037, p = 0.023 and p < 0.001, respectively). These
three factors formed a score with 1 point each for tumor load >20 %, CEA >130 ng/ml or CA19-9 > 200U/ml and
Karnofsky index <80 %. Patients with a score of 0 and 1 displayed a median OS of 10.4 months. Patients with a
score of 2 and 3 demonstrated a median OS of 5.1 months only (p < 0.001).
Conclusion: Overaggressive patient selection for Y90 radioembolization of liver dominant chemorefractory mCRC is
of questionable benefit. A scoring system comprising hepatic tumor load, CEA and CA19-9 serum levels and
Karnofsky index (TuCK-score) may support an improved patient selection. In our cohort of liver only versus liver
dominant disease, extrahepatic lung or lymphatic metastases did not significantly alter the prognosis.
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Background
In treatment-refractory liver dominant metastatic colo-
rectal cancer, the role of liver directed therapies still is
unclear. For Yttrium 90 (Y90) radioembolization (RE),
objective response rates between 33 and 48 % have been
published when applied in second line [1, 2], and
between 10 and 48 % in third line [3–6]. In a refractory
third line setting Seidensticker et al. reported improved
survival in a match pair study of 3.5 vs 8.3 months6.
Hendlisz et al. randomized between 5-fluorouracil (5-
FU) +/− Y90 radioembolization in refractory third line
patients and demonstrated a survival benefit of 10 versus
7.3 months, as well as a significant progression free sur-
vival (PFS) improvement of 4.3 vs 2.1 months. The latter
study led to inclusion of Y90 radioembolization in the
ESMO guidelines for colorectal cancer, however with a
low strength of recommendation (IV, B) [7].
In clinical practice, treatment recommendations for re-
fractory patients are challenging. Many patients present
with advanced tumor load in a biologically unfavorable
state of disease progression, potentially aggravated by
* Correspondence: Jens.Ricke@med.ovgu.de
1Department of Radiology and Nuclear Medicine, University of Magdeburg,
Leipziger Str. 44, 39120 Magdeburg, Germany
2Deutsche Akademie für Mikrotherapie e.V., Magdeburg, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Damm et al. BMC Cancer  (2016) 16:509 
DOI 10.1186/s12885-016-2549-x
comorbidities and a poor performance status. Palliation
in such patients must balance the patient´s desire for life
prolongation and an acceptable quality of life to with-
stand the hazards of aggressive treatments. Hence, a
careful patient selection is of utmost importance. For
Y90 radioembolization, no adequate predictive factors
have been published in treatment refractory colorectal
cancer patients yet, baring the risk of overtreatment as a
result of inappropriate patient selection.
In the study described herein we analyzed a cohort of
106 patients with chemo-refractory, liver dominant colo-
rectal cancer undergoing Y90 radioembolization at our
institution. We sought to determine predictive factors to
aid a responsible patient selection balancing the poten-
tial survival benefits against the inadvertent risk of an
aggressive liver directed therapy.
Methods
Study design and eligibility criteria
Our patient database was reviewed for patients with
colorectal cancer liver metastases undergoing Y90-
radioembolization in our department between 2006 and
2010. We collected retrospective data on prior surgical
or systemic treatments, disease spread, clinical perform-
ance, tumor markers and survival. All patients had been
scheduled for routine follow-up every 3 months at our
department including a documentation of their clinical
performance, disease response in Computed tomography
(CT)/magnetic resonance imaging (MRI) and laboratory
values. We selected all patients who met the following
criteria:
 liver metastases of colorectal carcinoma,
 admitted and eligible for Y90-radioembolization,
 salvage situation (either refractory to all accepted
chemotherapy regimen at the time of admission or
refusal of or non-eligibility to further systemic
therapies after at least one cycle).
Patient cohort
We included a total of 106 salvage patients with liver
metastases from colorectal cancer (70 male, 36 female;
mean age 61.9 years). All patients had failed at least one
chemotherapy regimen; the median number of chemo-
therapy lines applied was 3. 26 % of the patients had
failed four or more lines of systemic therapy. About half
of the patients had received bevacizumab (n = 67) and/or
cetuximab (n = 51) prior to radioembolization. 27 pre-
sented under maintenance therapy with capecitabine.
Other cytotoxic regimen such as a combination of mito-
mycin and 5-FU were applied to 7 patients before admit-
tance to Y90 radioembolization.
In 22 patients, a contraindication such as bone mar-
row depression or unwillingness to receive further
chemotherapies (mostly as a result of previous toxicity
such as polyneuropathy) led to discontinuation of sys-
temic therapies.
Thirty patients had previously undergone hepatic
resection or radiofrequency ablation before Y90 radio-
embolization. Whereas 86 patients presented liver
only disease, 30 patients demonstrated extrahepatic
tumor spread such as lymph node metastases (n = 17),
lung metastases (n = 16, with 15 patients displaying
more than one pulmonary metastases) and bone me-
tastases (n = 4). Further details of patient characteris-
tics are displayed in Table 1.
Clinical evaluation and radioembolization technique
All patients underwent a thorough clinical examin-
ation prior to radioembolization including a physical
examination, laboratory tests and cross-sectional im-
aging including MRI with hepatocyte-specific contrast
agent Gd-EOB-DTPA (Primovist®, Bayer HealthCare,
Leverkusen, Germany).
The technique of Y90 radioembolization has been de-
scribed in detailed elsewhere [8].
All patient scheduled for radioembolization received
an initial evaluation angiography. The work up
included coil or plug embolization of visceral col-
laterals if appropriate. After the test infusion of
Technecium-99 m macro-aggregated albumin (Tc-99 m
MAA, LyoMAA, Covidien, Neustadt, Germany) to the
liver arteries, a scintigraphy including a SPECT-CT
was performed to rule out extrahepatic accumulation
or inadvertent lung shunting. In the latter case, a
lung shunt above 10 % led to a dose reduction as
specified by the summary of product characteristics.
Dosimetry was performed applying the body-surface
area model [9].
Liver metastases were treated exclusively employing
resin microspheres (SIR-Spheres®, Sirtex Medical, Lane
Cove, Australia) labeled with beta-emitter Yttrium-90
(half-life 64 h; mean energy 0.96 MeV). The catheter
position during Y90 application was identical to the test
bolus of Tc-99 m MAA during the evaluation. Starting
in 2007, radioembolization was typically partitioned in
sequential therapies for each liver lobe at an interval of 4
to 6 weeks. In patients presenting with disease limited to
one liver lobe, Y90 spheres were applied in the according
lobe only with a dose calculation adopted to the reduced
liver volume [10]. Before 2007, we exclusively performed
whole liver treatments.
All patients gave written informed consent to both
radioembolization as well as the scientific use of their per-
sonal data. The institutional ethics committee deemed a
dedicated ethics vote unnecessary for the present analysis.
This scientific paper has been written according to the
reporting standards for radioembolization [11].
Damm et al. BMC Cancer  (2016) 16:509 Page 2 of 7
Data collection
Follow-up data was acquired until May 2013. The patient
database contained a prospective data set including therap-
ies prior to presentation at our institution (surgical resec-
tion, chemotherapy and combined immunochemotherapy),
tumor markers (Carcinoembryonic antigen, CEA and Can-
cer antigen 19–9, CA19-9 serum levels), individual patient
characteristics (age, sex, Karnofsky index) and imaging as-
pects (initial staging, tumor distribution and hepatic tumor
load). Finally, details of Y90 radioembolization (applied ac-
tivity, number of treatment sessions and more) were in-
cluded. Side effects were defined and categorized by the
Common Terminology Criteria for Adverse Events
(CTCAE, Version 4.03).
Statistical analysis
SPSS 21.0 (IBM®, New York, USA) was used for the en-
tire analysis. Descriptive analysis was computed with
median and range of continuous variables as well as
frequencies of nominal data. Univariate stepwise Cox re-
gression analysis was used to determine factors influen-
cing patient survival. Any factor with a tendency
towards significance (p ≤ 0.1) was included in a multi-
variate Cox proportional hazard model. Variables dem-
onstrating a significant influence on survival in the
multivariate regression analysis were used to create a
prognostic score. Binarization of the scoring parameters
was based on the median, the discrimination values were
then analyzed applying the Kaplan-Meier Method and
Log-rank test. All tests were two-sided, statistical signifi-
cance was assumed at a p < 0.05.
Results
Treatment and toxicities
We performed a total of 178 radioembolizations in 106
patients, including 12 whole-liver, 52 unilobar and 114
sequential lobar procedures. This resulted in a median
number of 2 treatment sessions per patient (range: 1 –
5). Repeated radioembolizations of a specified liver vol-
ume with at least 3 sessions were limited to 8 patients.
A median total activity of 1725 MBq (range: 200 –
3650 MBq) was administered per patient. The median
tumor load was 15.7 %(range: 1.0 – 63.0 %).
No acute mortality was observed within 30 days post
radioembolization. A total of 12 toxicities grade 3 or 4
according to CTCAE 4.02 were observed in 11 patients,
see Table 2. Seven patients developed radiation induced
Table 1 Patient characteristics
Patient characteristics
Female n = 36 33,9 %
Male n = 70 66,1 %
Age (median (range), years) 62.5 (33.0 -76.0)
Karnofsky index (median (range), %) 80 (60–100)
Pretreatment characteristics
Prior resection or radiofrequency ablation n = 30 28 %
Prior chemotherapy agents
Oxaliplatin (+5-fluorouracil) n = 79 75 %
Irinotecan (+5-fluorouracil) n = 89 84 %
Capecitabine n = 27 25 %
Bevacizumab n = 67 63 %
Cetuximab n = 51 48 %
Other n = 7 7 %
Overall chemotherapy lines (median (range)) 3 (1–5)
1st Line n = 9 8 %
2nd Line n = 35 33 %
3rd Line n = 34 32 %
4th Line and beyond n = 28 26 %
Tumor characteristics
UICC stage (median (range)) 4 (1–4)
Grading (median (range)) 2 (1–4)
Synchronous lymphatic metastases n = 80 75 %
Extrahepatic tumor sites prior to
radioembolization
n = 30 28 %
Solitary/oligonodular lung metastases n = 1 1 %
Diffuse lung metastases n = 15 14 %
Lymphatic metastases n = 17 16 %
Bone metastases n = 3 3 %
Hepatic tumor load (median (range), %) 15.7 (1.0–63.0)
CEA serum level (median (range), ng/ml) 130.1 (2.7–8713.3)
CA19-9 serum level (median (range), U/ml) 192.7 (0.3–32206.0)
Radioembolization procedures n = 178 100 %
Bilobar (total liver) n = 12 7 %
Unilobar n = 52 30 %
Sequential lobar n = 114 64 %
Treatment sessions per patient (median (range)) 2 (1–5)
Total activity per patient (median (range), MBq) 1725.0 (200.0–3650)
Table 2 Treatment associated toxicities according to the
Common Terminology Criteria for Adverse Events (CTCAE 4.03), a
total of 12 major toxicities (grade 3 or 4) occurred in 11 patients
Major treatment related toxicities (grade 3 or 4), 12 events in 11 patients:
Gastric or duodenal ulcer n = 3 (3 %)
Pleural effusion n = 1 (1 %)
Radiation induced cholecystitis n = 1 (1 %)
Radiation induced liver disease (RILD) presenting with n = 7 (7 %)
Refractory ascites n = 6 (6 %)
Liver failure n = 1 (1 %)
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liver disease (RILD) with ascites requiring paracentesis
(n = 6), in one case associated with liver failure without
tumor progression (n = 1). One patient displayed pleural
effusion requiring thoracocentesis. Symptomatic gastric
or duodenal ulcers occurred in three patients with sub-
sequent endoscopic interventions. One patient under-
went cholecystectomy after developing radiation induced
cholecystitis.
Primary outcome and concomitant therapy
Within the observation period, all patients deceased.
Hence, no censored patients occur in our survival ana-
lyses. The median follow-up was 6.0 months (range: 1.0
– 48.0 months). The median overall survival of all 106
patients was 6.7 months after the first radioembolization
as illustrated in the Kaplan-Meier survival curve (Fig. 1).
The median progression free survival assessed by
RECIST 1.1 was 3.5 months.In the follow-up period after
Y90-radioembolization, 13 patients were given mono-
therapy with newly available antibodies (e.g. panitumu-
mab). Another 9 patients received further cytotoxic
chemotherapy following Y90 radioembolization.
Regression analysis
At first, univariate stepwise Cox regression analysis was
carried out for patient demographics and individual per-
formance as well as tumor and treatment characteristics.
Regarding patient characteristics, a significant influ-
ence on patient survival was found for the Karnofsky
index (median 80 %, range 60 – 100 %; p = 0.014), but
not for age and sex. Prior resection or radiofrequency
ablation, the type of systemic therapy and the number of
chemotherapy lines before Y90 radioembolization had
no significant influence on patient survival.
The hepatic tumor load (median 15.7 %, range 1.0 –
63.0 %) was found a significant factor (p < 0.001) while
initial tumor staging, grading and extrahepatic manifes-
tations had no significant influence. Furthermore, the
serum level of specific tumor markers CEA (median
130.1 ng/ml, range 2.7 – 8713.3 ng/ml) and CA19-9
(median 192.7U/ml, range 0.3 - 32206.0 U/ml) were
identified as prognostic factors (p = 0.002 and p < 0.001,
respectively). Detailed parameters of radioembolization
(e.g. whole-liver treatment, number of treatment ses-
sions and administered activity of Y90) showed no sig-
nificant influence. The results of the univariate analysis
are summarized in Table 3.
In a second step, all factors with a p ≤ 0.1 were
included in a multivariate Cox regression. In this ana-
lysis, significant results were found for the Karnofsky
index (p = 0.037), hepatic tumor load (p = 0.001) and
serum levels of CEA and CA19-9 (p = 0.023 and p < 0.001,
respectively). Concomitant bone or lymphatic metastases
had no significant influence on the prognosis (p = 0.083
and p = 0.204, Table 3).
Clinical score
CEA and CA19-9 serum levels, hepatic tumor load and
Karnofsky index were further processed to form a prog-
nostic score.
We binarized these prognostic factors approximating
their median, identifying patients with:
 tumor load > 20 %,
 CEA level > 130 ng/ml and/or CA19-9 level > 200 U/
ml,
 Karnofsky index < 80 %.
Each of these poor prognostics factors was attrib-
uted a single point. Complete data was available for
87 patients (82 %).
Corresponding median survival was 13.4 months for pa-
tients displaying 0 points (n = 20), 8.3 months with 1 point
(n = 26), 5.8 months with 2 points (n = 26) and 4.0 months
with 3 points (n = 15), respectively (see Fig. 2). The log-
rank test confirmed a significant discrimination between
the according patient groups (p < 0.001).
When summarizing the groups of patients with 0 and
1 point versus 2 and 3 points, the according log-rank
test demonstrated a survival of 10.4 months vs.
5.1 months (p < 0.001, see Fig. 3).
Discussion
Y90 radioembolization has recently demonstrated its activity
in treatment naïve colorectal liver only disease with a liver-
only PFS improvement of 8 months when added to a FOL-
FOX first line treatment regimen [12]. However, the dominant
proportion of patients admitted to Y90 radioembolization
Fig. 1 Kaplan-Meier estimation for overall survival after first
radioembolization, all patients (n = 106). Since all patients had died
by the time of analysis, no censored patients occur in the graph.
Median overall survival (OS) was 6.7 months
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Table 3 Cox regression of potential factors to predict survival
Cox regression Hazard (95 % CI) Univariate P Multivariate P
Age 1.02 (1.00–1.04) 0.239
Sex‘ 0.76 (0.50–1.14) 0.179
Karnofsky index 0.98 (0.95–0.99) 0.014* 0.037**
Resection/RFA‘ 0.90 (0.56–1.44) 0.658
Oxaliplatin + 5-FU‘ 1.44 (0.91–2.26) 0.118
Irinotecan + 5-FU‘ 1.41 (0.82–2.46) 0.216
Capecitabine‘ 1.24 (0.79–1.94) 0.344
Bevacizumab‘ 0.87 (0.58–1.30) 0.492
Cetuximab‘ 1.26 (0.85–1.87) 0.243
Overall chemotherapy lines 1.14 (0.94–1.37) 0.179
UICC staging 1.01 (0.79–1.30) 0.286
Tumor grading 0.90 (0.64–1.28) 0.434
Lung metastases‘ 1.53 (0.85–2.74) 0.155
Lymphatic metastases‘ 1.60 (0.91–2.80) 0.100* 0.204
Bone metastases‘ 2.51 (0.89–7.13) 0.083* 0.083
Hepatic tumor load 1.05 (1.03–1.06) <0.001* 0.001**
CEA serum level 1.00 (1.00–1.00) 0.002* 0.023**
CA19-9 serum level 1.00 (1.00–1.00) <0.001* <0.001**
Bilobar Y90 RE‘ 0.89 (0.45–1.77) 0.740
Unilobar Y90 RE‘ 0.74 (0.35–1.55) 0.426
Sequential lobar Y90 RE‘ 0.82 (0.40–1.66) 0.775
Y90 RE sessions per patient 0.95 (0.72–1.24) 0.692
Total activity per patient 1.00 (0.99–1.00) 0.276
Results in the univariate analysis (*p < 0.1) were included in the multivariate analysis (**p < 0.05). Binary factors are marked (‘), other variables are ordinal
or continuous
Fig. 2 Kaplan-Meier estimation for overall survival after first
radioembolization, strata by score points (n = 87). Since all patients
had died by the time of analysis, no censored patients occur in the
graph. Median OS was 13.4 months (0 points, n = 20), 8.3 months (1
point, n = 26), 5.8 months (2 points, n = 26) and 4.0 months (3
points, n = 15), p < 0.001
Fig. 3 Kaplan-Meier estimation for overall survival (n = 87) after first
radioembolization, groups of patients with survival benefit (score of
0/1) vs. no survival benefit (score of 2/3). Since all patients had died
by the time of analysis, no censored patients occur in the graph.
Median OS was 10.4 months (score 0 or 1) vs. 5.1 months (score 2 or
3), p < 0.001
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today presents in a salvage setting, with extensive liver tumor
load, reduced performance status, chemorefractory disease,
and a history of numerous and variable chemotherapy cycles
[3, 4, 6]. Our own study contributes data to this patient selec-
tion with poor prognosis, with a median Karnofsky of 80 %, a
tumor load of 20 %, and chemorefractory dise ase or patients
refusing further chemotherapy as a results of toxicity. A total
of 81 % patients presented with liver only disease, thirty-five
patients (33 %) had undergone 2 lines and 62 patients (58 %)
3 or more lines of chemotherapy.
In this rather dismal patient cohort, the median overall
survival of all patients undergoing Y90 radioembolization
was 6.7 months. As such, the indication for Y90 radioembo-
lization in our patient group may have been too aggressive,
and the survival rate was worse than documented in other
series of salvage mCRC Y90 radioembolization. Hendlisz
et al. described a median survival of 10 months combining
Y90 radioembolization and 5-FU (vs. 7.3 months in 5-FU
only); Cosimelli et al. 12.6 months in a single arm cohort;
Bester et al. 11.9 months versus 6.6 in control; and Seiden-
sticker et al. 8.3 months versus 3.5 in control [3–6].
As systemic last line treatment, mitomycin C combined
with capecitabine has been considered a well-tolerated sal-
vage option for a long time, however associated with very
low activity. Lim et al. published a cohort of 21 patients
with a median survival of 6.8 months, commenting that
there was no definitive contribution to increasing the
patients overall survival [13]. Harba et al. reported
7.8 months overall survival in oxaliplatin and irinotecan
refractory advanced mCRC [14]. More recently, the COR-
RECT study comparing cohorts receiving Regorafenib ver-
sus placebo reported outcomes of 6.4 versus 5.0 months
(HR 0.77) in 760 randomized patients [15], however asso-
ciated with ≥ grade 3 side effects hand-foot-skin-reaction,
fatigue, diarrhea, hypertension and rash in 17 %,10 %, 7 %,
7 % and 6 %, respectively. For panitumumab monotherapy
in KRAS wild type patients, van Cutsem et al. reported a
reasonable antitumor activity in refractory patients with a
median survival of 6.3 months [16].
Even though the pooled overall survival of all patients
was poor in our own study, the scoring system derived out
of this cohort holds promise for an improved patient selec-
tion. The score comprising of Tumor load, CA 19–9 and/
or CEA, as well as Karnofsky (TuCK) discriminated two
groups of patients with a median survival of 10.4 versus
5.1 months if each factor was attributed 1 point along with
summing up patients with 0 and 1 versus 2 and 3 points. It
is difficult to interpret whether the poor outcome of pa-
tients with 2 and 3 points reflects advanced disease stage
or rather an aggressive tumor biology or poor performance
status. The survival difference between the two groups (0
and 1 points vs. 2 and 3 points) truly mirrors a composite
of multiple, independent factors representing stage, biology
and individual patient performance, represented in our
study by tumor load, clinical performance status and
tumor markers. In addition, patients without these negative
factors (TuCK 0) reached a median, overall survival of
13.7 months, which we consider highly favourable in a
treatment refractory salvage situation. Interestingly, with
the term “liver dominant disease” not clearly defined today,
neither lung nor lymph node or bone metastases proved to
have a significant impact on survival in our cohort.
Side effects grade 3 and 4 in the overall cohort of pa-
tients were limited to 11 of 106 patients (10 %, with 12
events total), indicating that Y90 radioembolization was of
moderate toxicity in our patients. Hendlisz et al. in 2010
reported absence of any ≥ grade 3 event in 21 patients
randomized to a combination therapy of 5-FU and Y90
radioembolization [5]. These data compare favourably to
systemic salvage chemotherapeutic regimen such as by
Regorafenib monotherapy with 232 of 500 patients experi-
encing ≥ grade 3 events, 85 of those discontinuing treat-
ment for side effects (17 %) [15], and even to regimen
considered well tolerable such as Capecitabine and mitomy-
cin C with reports of 4 grade 3 or 4 toxicities in 19 patients
[13], and 18 grade 3 events in 36 patients [16]. For panitu-
mumab monotherapy, 2 % grade 4 toxicity have been re-
ported, and the most frequent toxicity was skin toxicity [17].
In our patient cohort with a history of extensive che-
motherapies and half of the patients displaying a hepatic
tumor load >20 %, liver function after radioembolization,
i.e. the subsequent development of radiation (radioem-
bolization) induced liver disease (RILD or REILD), is of
high interest according to the first description by Sangro
et al.[18]. With 7 patients (6 %) displaying clinical symp-
toms which can be attributed to the development of
RILD the incidence is lower than described previously
with up to 20 % in a population of mixed tumor entities.
We attribute this favorable outcome to the preventive ef-
fect of sequential lobar treatment at an interval of 4 to
6 weeks for the left and right liver lobe, as well as single
lobar treatments if applicable [10]. In addition, RILD
prevention by a drug regimen combining enoxaparin,
ursodeoxycholic acid and pentoxiphylline for 8 weeks
after treatment may have been beneficial [10, 19].
Conclusion
A score based on Tumor load, CEA and/or CA19-9 serum
level as well as the Karnofsky index demonstrated a close
association with patient outcome after Y90 radioemboliza-
tion in the salvage situation. Patients displaying more than
1 point may not benefit from liver directed Y90 radioem-
bolization; in those patients alternative systemic treat-
ments or best supportive care should be considered. In
our population with severe liver dominant disease, lung,
bone and lymph node metastases had no negative prog-
nostic effect. The role of combined salvage Y90 radioem-
bolization and systemic therapy remains unclear.
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